Results 61 to 70 of about 215,808 (286)

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study [PDF]

, 2018
Purpose: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated preclinical activity in non–small cell lung cancer (NSCLC).
Beckmann, Richard, Garrido, Pilar, Goldman, Jonathan W., Gutierrez, Martin, Hossain, Anwar, Jalal, Shadia, John, William J., Johnston, Erica L., Kambhampati, Siva Rama Prasad, Kelly, Karen, Kim, Edward S., Mahadevan, Daruka, Paz-Ares, Luis G., Provencio, Mariano, Schaefer, Eric, Shaheen, Monte, Turner, P. Kellie   +16 more
core   +2 more sources

Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis

Arthritis Care &Research, EarlyView.
Objective To evaluate the efficacy and safety of baricitinib in pediatric patients with active juvenile idiopathic arthritis–associated uveitis (JIA‐U) or chronic anterior antinuclear antibody–positive uveitis, who had an inadequate response to methotrexate (MTX) or biologic disease‐modifying antirheumatic drugs (bDMARDs).
Athimalaipet V. Ramanan, Catherine M. Guly, Gabriele Simonini, Stuart Y. Keller, Priyanka Sen, Thorsten Holzkaemper, Joana Araújo, Pierre Quartier   +7 more
wiley   +1 more source

Pharmacokinetics of Odronextamab, A Bispecific T‐Cell‐Engaging Antibody, in Adult Patients With Relapsed or Refractory B‐Cell Non‐Hodgkin Lymphoma

CPT: Pharmacometrics & Systems Pharmacology
Non‐Hodgkin lymphoma (NHL) is the fifth most common malignancy and accounts for 5% of all cancers in the US, with the largest proportion being B‐cell CD20 positive NHL.
Marçal Bravo Padros, Daniela J. Conrado, Kamal Srinivasan, Lutz O. Harnisch, John D. Davis, Min Zhu   +5 more
doaj   +1 more source

Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine:pharmacokinetic and dosage-related findings from a clinical trial in Uganda [PDF]

, 2006
BACKGROUND: A six-dose antimalarial regimen of artemether-lumefantrine (A/L) may soon become one of the most widely used drug combination in Africa, despite possible constraints with adherence and poor absorption due to inadequate nutrition, and a lack ...
Babigumira, Joseph, Bajunirwe, Francis, Biraro, Samuel, Checchi, Francesco, Ferradini, Laurent, Fogg, Carole, Grandesso, Francesco, Guthmann, Jean-Paul, Kigozi, Isaac, Kiguli, James, Kyomuhendo, Juliet, Piola, Patrice, Ruzagira, Eugene, Taylor, Walter R. J.   +13 more
core   +3 more sources

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

Influential predictors of azithromycin pharmacokinetics: a systematic review of population pharmacokinetics

Annals of Medicine
Introduction Azithromycin exhibits significant pharmacokinetic variability. Thus, dosage optimization is crucial for optimal therapeutic outcomes. This systematic review aims to analyze the population pharmacokinetics (PopPK) of azithromycin and identify
Janthima Methaneethorn, Zheng Jiao, Rowan AlEjielat, Totsapol Jirasomprasert   +3 more
doaj   +1 more source

Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures [PDF]

, 2016
Objective To describe changes in immune parameters observed during long-term methotrexate (MTX) therapy in patients with active rheumatoid arthritis (RA) and explore correlations with simultaneously measured MTX pharmacokinetic (PKC) parameters ...
Hamilton, Robert, Kremer, Joel M., Lawrence, David A., McInnes, Iain B.   +3 more
core   +1 more source

Response to Allopurinol and Febuxostat According to the Fractional Excretion of Urate in Men With Gout

Arthritis Care &Research, EarlyView.
Objective Body mass index (BMI), glomerular filtration rate (GFR), and pretreatment urate levels have been reported to influence the urate‐lowering response to allopurinol. We investigated whether the fractional excretion of uric acid (FEUA) also modulates this response and relates to oxypurinol concentrations.
Pascal Richette, Anouk Walter‐Petrich, Quang Dinh Nguyen, Matthieu Resche‐Rigon, Quang Huy Dinh Nguyen, Minh Duc Do, Thao Phuong Mai, Tuan Duc Nguyen, Fernando Perez‐Ruiz, Emmanuel Letavernier, Tristan Pascart, Augustin Latourte, Hang Korng Ea, Thomas Bardin   +13 more
wiley   +1 more source

Pemodelan Farmakokinetika Berbasis Populasi dengan R: Model Dua Kompartemen Ekstravaskuler

Jurnal Farmasi Galenika (Galenika Journal of Pharmacy), 2018
A Tutorial of two-compartment extravascular population-based pharmacokinetics modeling was performed by differential equations and non-linear mixed effect model approach.
Dion Notario
doaj   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, EarlyView.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source